ABSTRACT

Thevetia peruviana, widely recognized as the Lucky Nut, is a highly toxic plant with significant pharmacological potential, belonging to the Apocynaceae family. This plant is a reservoir of diverse bioactive compounds, notably cardiac glycosides such as thevetin A and thevetin B, which possess therapeutic properties but are associated with high toxicity. Its phytochemical composition also includes alkaloids, flavonoids, saponins, and tannins, which contribute to its antimicrobial, anti-inflammatory, antioxidant, and anticancer effects. However, the plant's pharmacological utility is constrained by limited knowledge of its pharmacokinetics— encompassing absorption, distribution, metabolism, and excretion (ADME)—and a lack of detailed understanding of the molecular mechanisms behind its actions. This study delves into the phytochemical makeup, pharmacokinetic profile, pharmacological activities, and molecular interactions of Thevetia peruviana. It identifies critical research gaps and underscores the necessity for advanced investigations to mitigate its toxicity while maximizing its therapeutic potential, thus addressing its dualistic nature. Keywords: Thevetia peruviana, pharmacokinetic, phytochemical, Apocynaceae etc.
Publication date: 01/04/2026

https://www.ijbpas.com/pdf/2026/April/MS_IJBPAS_2026_10062.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.4.10062